Tetanus-Diphtheria-Acellular Pertussis (Tdap)
ADACEL® Supplier: Sanofi Pasteur Limited
BOOSTRIX® Supplier: GlaxoSmithKline Inc.

INDICATIONS: 
A. Reinforcing dose in grade 9. 
B. Pregnant people in every pregnancy, ideally provided between 27-32 weeks of gestation. 
C. Completion of primary series in unimmunized or incompletely immunized children (7 years of age and older), adolescents and adults, including those with unknown immunization history. 
D. Booster dose for individuals 4 years of age and older who are up-to-date for polio immunization. 
E. Wound management (see Tetanus Prophylaxis in Wound Management).

RECOMMENDED BY THE NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION BUT NOT PROVIDED FREE IN BC:
Recommended based on Good Evidence:
- All adults should receive one dose of Tdap vaccine if they have not previously received a pertussis containing vaccine in adulthood.

DOSES AND SCHEDULE: 
A. Grade 9: 1 dose given as 0.5 mL IM 
B. Pregnant People: 1 dose given as 0.5 mL IM 
C. Children and Adolescents 7-17 years of age (inclusive): 
   - Booster dose for those who missed receiving DTaP-IPV at school entry: 
     - 1 dose given as 0.5 mL IM 

---

A. There is no minimum interval between a dose of Td and Tdap when Tdap is being given for pertussis protection.
B. Individuals born in 1989 or later who missed their adolescent dose of Tdap are eligible for one dose of Tdap.
C. Tdap should be given irrespective of previous Tdap immunization history. Although recommended at 27-32 weeks of gestation, Tdap may be given from 13 weeks up to the time of delivery. For more information see Part 2 – Special Populations, People who are Pregnant or Planning a Pregnancy.
D. Tdap-IPV is the preferred product if polio vaccine is also required, but separate Tdap and IPV may be used.
E. Tdap is not indicated for primary immunization of children less than 7 years of age.
F. For children 10 years of age and older who have not yet received their adolescent dose of Tdap.
G. Children who complete their primary series, or receive a booster dose of Tdap after their 10th birthday, do not require an additional dose of Tdap in grade 9.
Tetanus-Diphtheria-Acellular Pertussis (Tdap)
ADACEL®     Supplier: Sanofi Pasteur Limited
BOOSTRIX®    Supplier: GlaxoSmithKline Inc.

DOSES AND SCHEDULE (continued):

- Incompletely immunized children and adolescents:
  - If the first dose of DTaP-containing vaccine was administered after the 1<sup>st</sup> birthday, administer additional dose(s) in order to complete a 3-dose primary series. Given as:
    - Dose 1: 0.5 mL IM
    - Dose 2: 0.5 mL IM 4-8 weeks after 1<sup>st</sup> dose
    - Dose 3: 0.5 mL IM 6-12 months after 2<sup>nd</sup> dose
  - If the first dose of DTaP-containing vaccine was administered before the 1<sup>st</sup> birthday, administer additional dose(s) in order to complete a 4-dose primary series. Given as:
    - Dose 1: 0.5 mL IM
    - Dose 2: 0.5 mL IM 4-8 weeks after 1<sup>st</sup> dose
    - Dose 3: 0.5 mL IM 4-8 weeks after 2<sup>nd</sup> dose
    - Dose 4: 0.5 mL IM 6-12 months after 3<sup>rd</sup> dose

- Unimmunized children and adolescents:
  - 3 doses given as:
    - Dose 1: 0.5 mL IM
    - Dose 2: 0.5 mL IM 4-8 weeks after 1<sup>st</sup> dose
    - Dose 3: 0.5 mL IM 6-12 months after 2<sup>nd</sup> dose

Adults 18 years of age and older:
- Unimmunized or incompletely immunized adults completing a 3-dose series:
  - First dose given as Tdap, followed by 2 doses of Td, given as:
    - Dose 1: 0.5 mL IM
    - Dose 2: 0.5 mL IM 4-8 weeks after 1<sup>st</sup> dose
    - Dose 3: 0.5 mL IM 6-12 months after 2<sup>nd</sup> dose

ADMINISTRATION:
No additional requirements.

BOOSTER DOSES:
No booster doses are recommended at this time.

SEROLOGICAL TESTING:
Serological testing is not recommended before or after immunization.
**Tetanus-Diphtheria-acellular Pertussis (Tdap)**

**ADACEL®**  
Supplier: Sanofi Pasteur Limited

**BOOSTRIX®**  
Supplier: GlaxoSmithKline Inc.

**CONTRAINDICATIONS:**

1. History of an anaphylactic reaction to a previous dose of tetanus, diphtheria, or pertussis-containing vaccine or to any component of the product.
2. History of Guillain-Barré Syndrome (GBS) within 8 weeks of receipt of a tetanus-containing vaccine without any other cause being identified.

**PRODUCT COMPONENTS:**

**ADACEL®:**
Potential allergens: none.
Other components: aluminum phosphate, 2-phenoxyethanol, formaldehyde, glutaraldehyde.

**BOOSTRIX®:**
Potential allergens: polysorbate 80.
Other components: aluminum salts, disodium phosphate, formaldehyde, glutaraldehyde, glycine, monopotassium phosphate, potassium chloride.

**PRECAUTIONS:**
Not applicable.

**SPECIAL CONSIDERATIONS:**
Not applicable.

**ADVERSE EVENTS:**

**Local:** pain, redness, swelling. Local reactions may be more severe when tetanus-containing vaccines are provided after short intervals.

**Systemic:** fatigue, headache, fever, chills, nausea and diarrhea, muscle or joint aches.